Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | Dose-escalation results from the first-in-solid-tumor trial of modakafusp alfa

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the mechanism of action of the novel immuno-cytokine, modakafusp alfa, which consists of two interferon molecules fused to an anti-CD38 monoclonal antibody. Modakafusp alfa is currently being investigated in a Phase Ib/II trial, with dose escalation results being presented at ASCO 2022. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.